119 related articles for article (PubMed ID: 10955400)
1. Socioeconomic status and survival of persons with AIDS before and after the introduction of highly active antiretroviral therapy. Lazio AIDS Surveillance Collaborative Group.
Rapiti E; Porta D; Forastiere F; Fusco D; Perucci CA
Epidemiology; 2000 Sep; 11(5):496-501. PubMed ID: 10955400
[TBL] [Abstract][Full Text] [Related]
2. Impact of socioeconomic status on survival with AIDS.
Katz MH; Hsu L; Lingo M; Woelffer G; Schwarcz SK
Am J Epidemiol; 1998 Aug; 148(3):282-91. PubMed ID: 9690366
[TBL] [Abstract][Full Text] [Related]
3. Changes in survival among people with AIDS in Lazio, Italy from 1993 to 1998. Lazio AIDS Surveillance Collaborative Group.
Porta D; Rapiti E; Forastiere F; Pezzotti P; Perucci CA
AIDS; 1999 Oct; 13(15):2125-31. PubMed ID: 10546866
[TBL] [Abstract][Full Text] [Related]
4. Low socioeconomic status is associated with a higher rate of death in the era of highly active antiretroviral therapy, San Francisco.
McFarland W; Chen S; Hsu L; Schwarcz S; Katz M
J Acquir Immune Defic Syndr; 2003 May; 33(1):96-103. PubMed ID: 12792361
[TBL] [Abstract][Full Text] [Related]
5. [Social inequalities in survival of people with AIDS].
Palange S; Porta D; Forastiere F; Perucci CA
Epidemiol Prev; 2005; 29(1):26-32. PubMed ID: 15948647
[TBL] [Abstract][Full Text] [Related]
6. AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a National Health System?
Borrell C; Rodríguez-Sanz M; Pasarín MI; Brugal MT; García-de-Olalla P; Marí-Dell'Olmo M; Caylà J
Eur J Public Health; 2006 Dec; 16(6):601-8. PubMed ID: 16698886
[TBL] [Abstract][Full Text] [Related]
7. [AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era].
Zucchetto A; Bruzzone S; De Paoli A; Regine V; Pappagallo M; Dal Maso L; Serraino D; Rezza G; Suligoi B
Epidemiol Prev; 2009; 33(4-5):184-9. PubMed ID: 20124634
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category.
Pérez-Hoyos S; del Amo J; Muga R; del Romero J; García de Olalla P; Guerrero R; Hernàndez-Aguado I;
AIDS; 2003 Feb; 17(3):353-9. PubMed ID: 12556689
[TBL] [Abstract][Full Text] [Related]
9. [A retrospective cohort study on survival time of AIDS death cases receiving Antiretroviral Therapy and related factors].
Hao L; Zhu X; Wang G; Lin B; Qian Y; Tao X; Hu J; Yang X; Kang D
Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Jun; 48(6):466-70. PubMed ID: 25219434
[TBL] [Abstract][Full Text] [Related]
10. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
[TBL] [Abstract][Full Text] [Related]
11. Race, sex, drug use, and progression of human immunodeficiency virus disease.
Chaisson RE; Keruly JC; Moore RD
N Engl J Med; 1995 Sep; 333(12):751-6. PubMed ID: 7643881
[TBL] [Abstract][Full Text] [Related]
12. Is it possible to reduce AIDS deaths without reinforcing socioeconomic inequalities in health?
Antunes JL; Waldman EA; Borrell C
Int J Epidemiol; 2005 Jun; 34(3):586-92. PubMed ID: 15737970
[TBL] [Abstract][Full Text] [Related]
13. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City.
Sackoff JE; Hanna DB; Pfeiffer MR; Torian LV
Ann Intern Med; 2006 Sep; 145(6):397-406. PubMed ID: 16983127
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
[TBL] [Abstract][Full Text] [Related]
15. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
16. Mortality Risk After AIDS-Defining Opportunistic Illness Among HIV-Infected Persons--San Francisco, 1981-2012.
Djawe K; Buchacz K; Hsu L; Chen MJ; Selik RM; Rose C; Williams T; Brooks JT; Schwarcz S
J Infect Dis; 2015 Nov; 212(9):1366-75. PubMed ID: 26044289
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral therapy and declining AIDS mortality in New York City.
Messeri P; Lee G; Abramson DM; Aidala A; Chiasson MA; Jessop DJ
Med Care; 2003 Apr; 41(4):512-21. PubMed ID: 12665715
[TBL] [Abstract][Full Text] [Related]
18. Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. Tuscany AIDS Study Group.
Pezzotti P; Napoli PA; Acciai S; Boros S; Urciuoli R; Lazzeri V; Rezza G
AIDS; 1999 Feb; 13(2):249-55. PubMed ID: 10202831
[TBL] [Abstract][Full Text] [Related]
19. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004.
Schneider MF; Gange SJ; Williams CM; Anastos K; Greenblatt RM; Kingsley L; Detels R; Muñoz A
AIDS; 2005 Nov; 19(17):2009-18. PubMed ID: 16260908
[TBL] [Abstract][Full Text] [Related]
20. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
